Compare IDAI & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDAI | NCEL |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 20.7M |
| IPO Year | N/A | N/A |
| Metric | IDAI | NCEL |
|---|---|---|
| Price | $3.72 | $2.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 158.6K | 82.3K |
| Earning Date | 11-14-2025 | 12-01-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,727,824.00 | N/A |
| Revenue This Year | $3.46 | N/A |
| Revenue Next Year | $219.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 72.57 | N/A |
| 52 Week Low | $1.43 | $2.91 |
| 52 Week High | $18.75 | $7.64 |
| Indicator | IDAI | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 42.08 | N/A |
| Support Level | $4.00 | N/A |
| Resistance Level | $4.57 | N/A |
| Average True Range (ATR) | 0.34 | 0.00 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 8.08 | 0.00 |
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.